Association of the IL-17 polymorphisms with serum IL-17 levels in AG patients.

The serum IL-17A and IL-17F level were measured in different genotype carriers from AG patients. A) The expression of IL-17A level was no difference between the 15 AA homozygotes, 24 AG heterozygotes carriers and 9 GG homozygotes carriers of IL-17A rs2275913 polymorphism. (P>0.05; respectively); B) The expression of IL-17F level was no difference between the 2 CC homozygotes, 14 CT heterozygotes carriers and 62 TT homozygotes carriers of IL-17F rs763780 polymorphism (P>0.05; respectively).</p

The genotypic and allelic frequencies of rs2275913, rs763780 and rs4819554 between cases and controls.

<p>The genotypic and allelic frequencies of rs2275913, rs763780 and rs4819554 between cases and controls.</p

Demographic and clinical characteristics of cases and controls.

<p>Demographic and clinical characteristics of cases and controls.</p

Levels of serum IL-17A and IL-17F in the AG, IG and control groups.

<p>Serum IL-17A and IL-17F levels of 78 AG patients, 150 IG patients and 198 control subjects were detected using Elisa kit. Expression of serum IL-17A and IL-17F were significantly decreased in the AG and IG group compared with controls (P<0.001; respectively), whereas no significant difference was observed between the AG and IG groups (both P>0.05). AG represents acute gout; IG represents intercritical periods of gout. The ANOVA and Bonferroni's test methods were used. The statistical significance was set at P<0.05.</p

The demographic and clinical characteristics of PE and control groups.

<p>The demographic and clinical characteristics of PE and control groups.</p